Benign Prostatic Hyperplasia Clinical Trial
Official title:
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
Prostate adenoma or benign prostatic hypertrophy (BPH) is a benign disease of the prostate gland. It results in an increase in the volume of the prostate area located in contact with the urethra. Compression of the prostatic urethra by the adenoma can cause lower urinary tract disorders. The classic treatments in case of failure of medical treatment are endoscopic resection of the prostate and adenomectomy, but these techniques are characterized by a significant hemorrhagic risk that may require transfusions and prolonged hospitalization. Minimally invasive treatments with low morbidity have been developed to overcome these drawbacks. They allow to propose a therapeutic solution adapted to patients: not tolerating their medical treatment, wishing to keep antegrade ejaculation, elderly and/or frail, at risk of bleeding, wishing an ambulatory treatment, refusing the conventional surgical techniques. The Focal One® device was developed to treat prostate cancer using ultrasound energy. This energy is delivered through a probe placed in your rectum. Connected to this probe, an ultrasound machine will allow your doctor to see precisely which part of your prostate is being treated. By heating the prostate tissue to a very high temperature in one treatment session, the energy delivered will then destroy the tissue. Ultrasound guidance coupled with the localized nature of the treatment allows the targeted area to be treated while respecting the prostate tissue and structures adjacent to the prostate and thus reducing side effects. Treatment of prostate adenoma with HIFU would allow for localized destruction to reduce prostate volume. The reduction of the compression of the prostatic urethra thus obtained would allow an improvement of the urinary disorders. The treatment is performed transrectally under real-time ultrasound control, which allows the adjacent structures to be respected, thus preserving antegrade ejaculation and limiting the side effects.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | June 2022 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Over 50 years of age, - BPH greater than 30 cc confirmed by endorectal ultrasound - IPSS score > 7, Qol-IPSS > 2, IIEF-5 score > 11 - Qmax < 15 ml/s or urinary retention (in indwelling catheter, self-catheterization, or with an RPM > 300 cc). - In failure or intolerance of drug treatment(s) for BPH - negative cytobacteriological examination of the urine Exclusion Criteria: - Prostate volume > 80 ml - Presence of a median lobe - Men allergic to latex - Contraindication to the insertion of a transrectal HIFU probe: rectal fistula, anal or rectal fibrosis, or other abnormalities - History of prostate surgery - History of prostate radiation therapy - History of bladder cancer - Current anti-coagulant treatment with a stopping window that cannot exceed 48 hours at the time of the HIFU procedure - Presence of a urinary tract fistula - History of inflammatory bowel disease - Ongoing urogenital infection - Neurological bladder pathology - History of urethral stenosis - Confirmed or suspected prostate cancer - Contraindication to surgery (including anesthesia) - Contraindication to pelvic MRI - Presence of metallic implants or stents in the urethra - Presence of prostatic calcification whose location interferes with HIFU treatment - Patients with renal failure with a GFR <35ml/min |
Country | Name | City | State |
---|---|---|---|
France | Hopital Edouard Herriot, service d'urologie | Lyon |
Lead Sponsor | Collaborator |
---|---|
EDAP TMS S.A. |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The safety of HIFU treatment will be assessed by analyzing adverse events (serious and non-serious) reported during follow-up. | 3 months | ||
Secondary | Evaluation of treatment performance by maximum urine output (Qmax) | 1 and 3 months | ||
Secondary | Evaluation of treatment performance by residual post-void volume (RPM) | 1 and 3 months | ||
Secondary | Evaluation of voiding symptomatology with IPSS questionnaire | 1 and 3 months | ||
Secondary | Evaluation of quality of urinary life with Qol-IPSS score | 1 and 3 months | ||
Secondary | Evaluation of quality of erection with IIEF-5 questionnaire | 1 and 3 months | ||
Secondary | Evaluation of ejaculation quality with MSHQ-SF questionnaire | 1 and 3 months | ||
Secondary | Evaluation of continence with ICIQ-SF questionnaire | 1 and 3 months | ||
Secondary | Evaluation of the global impression of improvement scale with PGI-1 questionnaire | 1 and 3 months | ||
Secondary | Evaluation of the change in the PSA rate | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04807296 -
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
|
N/A | |
Recruiting |
NCT05574244 -
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT04245566 -
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
|
Phase 3 | |
Completed |
NCT03246880 -
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
|
Phase 3 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT02283684 -
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
|
Phase 4 | |
Completed |
NCT02206243 -
Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
|
||
Completed |
NCT01438775 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT01454349 -
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
|
Phase 1/Phase 2 | |
Completed |
NCT01152190 -
A Study in Benign Prostatic Hyperplasia
|
Phase 3 | |
Completed |
NCT01139762 -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
|
Phase 3 | |
Active, not recruiting |
NCT00400894 -
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
N/A | |
Unknown status |
NCT00381108 -
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
|
Phase 1 | |
Completed |
NCT00224133 -
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
|
Phase 3 | |
Completed |
NCT00701779 -
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
|
Phase 4 | |
Terminated |
NCT02962674 -
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Completed |
NCT04831476 -
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
|